Neurogastrx rakes in $60m Series B

Neurogastrx, a developer of treatments for gastrointestinal disorders, has secured $60 million in Series B funding.

Neurogastrx, a developer of treatments for gastrointestinal disorders, has secured $60 million in Series B funding. Vivo Capital led the round with participation from other backers that included RTW Investments, Samsara BioCapital, Marshall Wace, 5AM Ventures, venBio and OrbiMed Advisors.

Source: Press Release